333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com
Sector(es): Healthcare
Industria: Drug Manufacturers - General
Empleados a tiempo completo: 18,000
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Daniel P. O'Day | Chairman & CEO | 6.52M | N/D | 1964 |
Mr. Andrew D. Dickinson | Chief Financial Officer | 2.48M | N/D | 1970 |
Ms. Deborah H. Telman | Executive VP of Corporate Affairs, General Counsel & Corporate Secretary | 2.39M | N/D | 1965 |
Ms. Johanna Mercier | Chief Commercial Officer | 2.89M | N/D | 1970 |
Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 2.6M | N/D | 1964 |
Ms. Sandra Patterson | Senior VP, Corporate Controller & Principal Accounting Officer | N/D | N/D | 1967 |
Ms. Jacquie Ross C.F.A. | Vice President of Investor Relations | N/D | N/D | N/D |
Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | N/D | N/D | 1976 |
Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | N/D | N/D | 1962 |
Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe | N/D | N/D | 1946 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
La calificación ISS Governance QuickScore de Gilead Sciences, Inc. a partir del 1 de mayo de 2024 es 2. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 1; Compensación: 4.